Cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis: current perspectives
Béla Z Schmidt,1 Jérémy B Haaf,2 Teresinha Leal,2 Sabrina Noel,2 1Stem Cell Biology and Embryology, Department of Development and Regeneration, Katholieke Universiteit Leuven, Leuven, 2Louvain Center for Toxicology and Applied Pharmacology, Université Cath...
Guardado en:
Autores principales: | Schmidt BZ, Haaf JB, Leal T, Noel S |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://doaj.org/article/3216efb0df3941889a5dd4ef20f40d88 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Obesity in cystic fibrosis
por: Katherine A. Kutney, et al.
Publicado: (2021) -
XV-2c and KM: 19 haplotype analysis in Chilean patients with cystic fibrosis and unknown CFTR gene mutations
por: REPETTO,GABRIELA M, et al.
Publicado: (2007) -
Long-Term Outcomes in Real Life of Lumacaftor–Ivacaftor Treatment in Adolescents With Cystic Fibrosis
por: Stéphanie Bui, et al.
Publicado: (2021) - Journal of cystic fibrosis
-
Integrity and Stability of PTC Bearing CFTR mRNA and Relevance to Future Modulator Therapies in Cystic Fibrosis
por: Luka A. Clarke, et al.
Publicado: (2021)